Retatrutide (GLP-3R) 10mg Dosage Protocol

Quickstart Highlights

Retatrutide is an investigational triple-receptor agonist peptide targeting GLP-1, GIP, and glucagon receptors, under development for obesity and type 2 diabetes.

Phase 2 trials have shown remarkable weight-loss efficacy, with participants losing up to 24% of body weight at 48 weeks on higher doses.
This protocol provides an educational framework for once-weekly subcutaneous administration with gradual titration to reduce gastrointestinal side effects.

Preparation & Storage:

Reconstitute with 1.0 mL bacteriostatic water → ~10 mg/mL
Dose range: 2–8 mg weekly (gradual escalation over 8–12 weeks)
Measurement: 1 unit (U-100 syringe) = 0.01 mL ≈ 100 mcg
Lyophilized: Freeze at −20 °C (−4 °F)
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (1 mL ≈ 10 mg/mL)

Phase	Weekly Dose	Units (per injection) (mL)
Weeks 1–4	2 mg	20 units (0.20 mL)
Weeks 5–8	4 mg	40 units (0.40 mL)
Weeks 9–12	6 mg	60 units (0.60 mL)
Weeks 13+	8 mg	80 units (0.80 mL)

Frequency:

Volumes >1.0 mL should be split into 2 injections at separate sites for optimal absorption

Reconstitution Steps

Draw 1.0 mL bacteriostatic water using a sterile syringe
Inject slowly along the vial wall; avoid foaming
Gently swirl or roll until fully dissolved (do not shake)
Label with preparation date
Refrigerate at 2–8 °C, protected from light
Use within 4 weeks

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Advanced / Aggressive Protocol (1 mL ≈ 10 mg/mL)

Phase	Weekly Dose	Units (per injection) (mL)
Weeks 1–4	2 mg	20 units (0.20 mL)
Weeks 5–8	4 mg	40 units (0.40 mL)
Weeks 9–12	8 mg	80 units (0.80 mL)
Weeks 13+	12 mg	120 units (1.20 mL)

*The 12 mg dose (highest tested in Phase 2) requires combining 2 vials, drawing 1.2 mL total, and splitting into 2 subcutaneous injections. Gradual titration is critical to reduce gastrointestinal side effects.

Note: This protocol is for educational purposes only. Retatrutide is not FDA-approved and should only be used in research settings following trial protocols.

Supplies Needed

Retatrutide vials (10 mg each)
- 12-week standard (up to 6 mg): 5 vials
- 24-week standard (up to 8 mg): 15 vials
- 12-week aggressive (up to 8 mg): 6 vials
U-100 Insulin Syringes (1 mL)
- 1–2 syringes per week depending on dose
- 12-week: 12–24 syringes
- 24-week: 24–48 syringes
Bacteriostatic Water (10 mL bottles)
- 1 mL per vial for reconstitution
- 12-week: 5 mL → 1 bottle
- 24-week: 15 mL → 2 bottles
Alcohol Swabs
- 1 per vial + 1–2 per injection site
- 12-week: ~50 swabs → 1 × 100-count box
- 24-week: ~100 swabs → 1 × 100-count box

Protocol Overview

Goal: Achieve substantial weight loss and metabolic improvements through triple-receptor activation
Schedule: Weekly subcutaneous injections for 12–48 weeks
Dose Range: 2–12 mg weekly with 4-week titration steps
Reconstitution: 1 mL per 10 mg vial (~10 mg/mL)
Storage: Frozen lyophilized at −20 °C; reconstituted refrigerated for 4 weeks

Dosing Protocol

Start: 2 mg weekly for 4 weeks
Escalation: Increase by 2–4 mg every 4 weeks as tolerated
Target Dose:
- Standard: 6–8 mg weekly
- Advanced: 12 mg weekly
Frequency: Same day each week
Cycle Length: Minimum 24 weeks; trials extended to 48 weeks
Timing: Consistent day/time; rotate injection sites

Storage Instructions

Proper storage is essential to maintain peptide stability and integrity.

Lyophilized (Unmixed): Store in a freezer at approximately −20°C (−4°F) for long-term preservation. If freezing is not available, refrigeration (2–8°C) is acceptable for shorter durations. Keep in a dry, dark environment away from moisture.
After Reconstitution: Store the solution in a refrigerator at 2–8°C (35.6–46.4°F) at all times. Do not freeze once mixed.
Shelf Life: Use within 28 days after reconstitution for optimal stability and reliability. Discard any remaining solution after this period.

Important Notes

Key considerations for consistency, handling, and research accuracy.

Always use a new, sterile insulin syringe for each administration; do not reuse needles
Follow proper aseptic technique: clean both the vial stopper and injection site with separate alcohol swabs and allow to dry fully
Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation and avoid tissue buildup
Administer injections slowly and steadily, allowing a few seconds before withdrawing the needle
Keep a record of dosing, timing, and injection sites to maintain consistency throughout the protocol
Do not use the solution if it appears cloudy, discolored, or contains visible particles
Store and handle peptides according to recommended conditions to preserve stability

How This Works

Retatrutide activates GLP-1, GIP, and glucagon receptors:

GLP-1 & GIP: Enhance glucose-dependent insulin secretion, suppress appetite
Glucagon: Increases metabolic rate, promotes energy expenditure, and enhances fat burning
Extended Half-Life (~6 days): Supports once-weekly dosing
Overall Effect: Reduced calorie intake, increased satiety, enhanced lipid oxidation, and improved glycemic control

Potential Benefits & Considerations

Benefits

Weight Loss: 22–24% body weight reduction at 48 weeks (8–12 mg doses)
Glycemic Control: HbA1c reduction of 1.3–2.0% in T2DM patients; ~82% reached HbA1c ≤6.5%
Cardiometabolic: Lower BP, LDL cholesterol, waist circumference, liver fat; >80% hepatic steatosis resolution
Universal Response: 100% achieved ≥5% weight loss on high doses

Side Effects

Mild-to-moderate GI symptoms: nausea, vomiting, diarrhea during dose escalation
Dose-dependent and transient
No severe hypoglycemia or serious treatment-related adverse events
Safety profile comparable to GLP-1 agonists when properly titrated

Lifestyle Factors

Follow a balanced diet to support metabolic and endocrine pathways
Maintain proper hydration for optimal physiological function
Prioritize sleep and recovery to support hormonal balance
Engage in regular physical activity to complement metabolic research models
Manage stress levels, as stress can impact hormone signaling
Avoid excessive processed foods when focusing on metabolic studies

Injection Technique

General guidance for subcutaneous administration:

Clean the vial stopper and injection area with alcohol and allow to dry
Gently pinch the skin and insert the needle at a 45–90° angle
Inject slowly and steadily without aspirating
Hold the needle in place for a few seconds before removing
Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation

Recommended Source

We recommend Fit Aminos for high-purity research peptide products.

Why Fit Aminos?

High-purity, lab-tested peptide batches with quality verification.
Consistent handling and preparation processes designed to support reliable research protocols.
Transparent sourcing and dependable fulfillment for research-grade compounds.

Shop at Fit Aminos

Important Note

This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.

References

The Lancet (2023)
— Rosenstock J, et al. Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss)

New England Journal of Medicine (2023)
— Jastreboff AM, et al. Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss)

American Diabetes Association (2023)
— ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data)

ADA Meeting News (2023)
— Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage)

ClinicalTrials.gov
— Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760; protocol details, dosing regimens)